dc.contributor.author | Felip, E | |
dc.contributor.author | Hirsh, V | |
dc.contributor.author | Popat, S | |
dc.contributor.author | Cobo, M | |
dc.contributor.author | Fülöp, A | |
dc.contributor.author | Dayen, C | |
dc.contributor.author | Trigo, JM | |
dc.contributor.author | Gregg, R | |
dc.contributor.author | Waller, CF | |
dc.contributor.author | Soria, J-C | |
dc.contributor.author | Goss, GD | |
dc.contributor.author | Gordon, J | |
dc.contributor.author | Wang, B | |
dc.contributor.author | Palmer, M | |
dc.contributor.author | Ehrnrooth, E | |
dc.contributor.author | Gadgeel, SM | |
dc.date.accessioned | 2017-08-11T15:07:50Z | |
dc.date.issued | 2018-01 | |
dc.identifier.citation | Clinical lung cancer, 2018, 19 (1), pp. 74 - 83.e11 | |
dc.identifier.issn | 1525-7304 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/767 | |
dc.identifier.eissn | 1938-0690 | |
dc.identifier.doi | 10.1016/j.cllc.2017.06.002 | |
dc.description.abstract | Introduction In the phase III LUX-Lung 8 trial, afatinib significantly improved progression-free survival (PFS) and overall survival (OS) versus erlotinib in patients with squamous cell carcinoma (SCC) of the lung progressing during or after platinum-based chemotherapy. Patient-reported outcomes (PROs) and health-related quality of life (QoL) in these patients are presented.Patients and methods Patients (n = 795) were randomized 1:1 to oral afatinib (40 mg/d) or erlotinib (150 mg/d). PROs were collected (baseline, every 28 days until progression, 28 days after discontinuation) using the European Organization for Research and Treatment of Cancer QoL questionnaire and lung cancer-specific module. The percentage of patients improved during therapy, time to deterioration (TTD), and changes over time were analyzed for prespecified lung cancer-related symptoms and global health status (GHS)/QoL.Results Questionnaire compliance was 77.3% to 99.0% and 68.7% to 99.0% with afatinib and erlotinib, respectively. Significantly more patients who received afatinib versus erlotinib experienced improved scores for GHS/QoL (36% vs. 28%; P = .041) and cough (43% vs. 35%; P = .029). Afatinib significantly delayed TTD in dyspnea (P = .008) versus erlotinib, but not cough (P = .256) or pain (P = .869). Changes in mean scores favored afatinib for cough (P = .0022), dyspnea (P = .0007), pain (P = .0224), GHS/QoL (P = .0320), and all functional scales. Differences in adverse events between afatinib and erlotinib, specifically diarrhea, did not affect GHS/QoL.Conclusion In patients with SCC of the lung, second-line afatinib was associated with improved prespecified disease-related symptoms and GHS/QoL versus erlotinib, complementing PFS and OS benefits with afatinib. | |
dc.format | Print-Electronic | |
dc.format.extent | 74 - 83.e11 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Carcinoma, Squamous Cell | |
dc.subject | Lung Neoplasms | |
dc.subject | Platinum Compounds | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Neoplasm Staging | |
dc.subject | Survival Analysis | |
dc.subject | Quality of Life | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Erlotinib Hydrochloride | |
dc.subject | Patient Reported Outcome Measures | |
dc.subject | Afatinib | |
dc.title | Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-06-13 | |
rioxxterms.versionofrecord | 10.1016/j.cllc.2017.06.002 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Clinical lung cancer | |
pubs.issue | 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 19 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Thoracic Oncology | en_US |
dc.contributor.icrauthor | Popat, Sanjay | |
dc.contributor.icrauthor | Marsden, | |